Eight projects in medtech, biotech and pharma have been awarded the Proof of Concept (POC) grant by BioInnovation Institute.
More than 70 projects applied for the POC grant which is available to projects with a clear commercial focus as BioInnovation Institute works to bring research out of the lab and into the economy for the benefit of human welfare.
Each accepted project will receive between DKK 695.000 and DKK 1M.
The BII Board of Directors has been supported by a committee of life science experts in choosing the eight projects. The projects will continue to work at their current institution or workplace to establish the preliminary proof of concept of their research during the 12 months long program.
“We are very pleased to see so many early projects with strong science from the universities focus on the commercial potential of their research. We continuously receive many applications for all of our programs and with the Proof of Concept grant the universities science projects will take the very first step towards the market to benefit patients”, says Hervør Lykke Olsen, scientific advisor, BII.
If you are ready to establish the preliminary proof of concept of your project and if your research has commercial potential, BioInnovation Institute is right now looking for applications from medtech, biotech and pharma projects. Apply before August 15.
Congratulations to the accepted projects!
Birgitte Holst from University of Copenhagen for the pharma project: Anti-obesity effect of combination therapy acting on different neuronal populations, that allows for synergistic action on appetite regulation.
Rikke Olsen from University of Copenhagen for the pharma project: Promising novel antimicrobial compounds – in vivo assessment.
Søren Kjærulff from Lactobio ApS for the industrial biotech project: Topical antimicrobial solution for resistant Staphylococcus infections in inflammatory skin diseases e.g. atopic dermatitis.
Karin Lykke-Hartmann from Aarhus University for the pharma project: New approach to help low responders in infertility treatment.
Claus Graff from Aalborg University for the medtech project: Cardiac Resynchronization in Heart Failure: The SynchroGram.
Bolette Hartmann from Bainan Biotech for the pharma project: A gut approach to treating osteoporosis.
Ulf Simonsen from Aarhus University for the pharma project: Modulation of transglutaminase 2 conformation as treatment to prevent cardiovascular complications in diabetes.
Michael Krogh Jensen from DTU on the industrial biotech project: Microbial production of commercial anticancer therapeutics.